Focal Interest
Focal Interest

Cancer Immunotherapy and Biomarkers

External reference: https://openalex.org/T10158

  1. Combination therapy showed a temporary response in metastatic DDCS
    Case report demonstrates promising response to pembrolizumab and pazopanib combination therapy in metastatic dedifferentiated chondrosarcoma, highlighting emerging systemic treatment options.
  2. Short-course anti-TB therapy followed regression of reactivated focus
    Case report of ICI-induced TB reactivation managed with short-course anti-TB therapy followed by continued checkpoint inhibitor monotherapy, suggesting personalized management alternatives to.
  3. FMT with immunotherapy showed activity in NSCLC and melanoma
    Phase 2 trial: donor FMT plus first-line ICI in NSCLC and melanoma showed high ORRs and implicates loss of specific bacterial taxa in association with response.